Qiagen, NL0015002SN0

Qiagen stock: Shareholders approve Pratt as CEO

Published on 11/16/2026 at 17:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen stock enters a new leadership phase after shareholders approved Jonathan M. Pratt as CEO and managing director. The EQT deal remains pending.

Leadership change enters focus

  • Shareholders approved Jonathan M. Pratt as Qiagen's CEO and managing director at an extraordinary general meeting.
  • The transition comes as Qiagen operates under a pending EQT takeover agreement and suspended 2026 guidance.
Qiagen, NL0015002SN0, Illustration mit AI erstellt.

Shareholders approved Jonathan M. Pratt as Qiagen's CEO and managing director at an extraordinary general meeting on November 6, 2026. The leadership decision adds a fresh corporate milestone for the molecular diagnostics company as investors assess its pending transaction with EQT.

The approval formalizes Pratt's move into Qiagen's top executive role after he joined the company as chief executive officer on September 1. Thierry Bernard stepped down as CEO and managing board member on the same date, while CFO Roland Sackers remains on the managing board, according to Yahoo Finance.

Takeover remains the central backdrop

Pratt takes the leadership role while Qiagen's recommended all-cash takeover by EQT remains pending. Qiagen has suspended its 2026 outlook while the transaction is pending, keeping execution and the deal timetable central to the investment case.

The leadership change gives investors a new point of focus for future updates on automation, digital PCR, bioinformatics and QuantiFERON. The company will continue operating under its current management until the proposed transaction is completed.

Qiagen stock at Lang & Schwarz

Qiagen stock traded at 45.26 euros on Lang & Schwarz at 17:48 Berlin time on Monday, November 16.

Qiagen company facts

  • Company: Qiagen N.V.
  • ISIN: NL0015002SN0
  • Trading venue: Lang & Schwarz
  • Price: 45.26 euros at 17:48 Berlin time on November 16, 2026

For broader market developments, see Current market reports.

More company news and analysis is available on More news and analyses on Qiagen stock.

Disclaimer...
en | NL0015002SN0 | QIAGEN | boerse | 70521908 | bgmi